Initiation of Take-Home Medication Dosing and Methadone Maintenance Treatment Effectiveness
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853615
Methadone maintenance treatment (MMT) arguably remains the most effective medication treatment for opioid use disorder (OUD), but concerns about medication diversion and safety have historically limited MMT access. Limited data on take-home medication dosing during MMT has contributed to striking national differences in the approach to take-home dosing. The COVID-19 pandemic and calls among people who use drugs for better MMT services recently drove many nations to expand take-home dosing, creating opportunities for comparative evaluation of take-home dosing and MMT effectiveness.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853615
Methadone maintenance treatment (MMT) arguably remains the most effective medication treatment for opioid use disorder (OUD), but concerns about medication diversion and safety have historically limited MMT access. Limited data on take-home medication dosing during MMT has contributed to striking national differences in the approach to take-home dosing. The COVID-19 pandemic and calls among people who use drugs for better MMT services recently drove many nations to expand take-home dosing, creating opportunities for comparative evaluation of take-home dosing and MMT effectiveness.
Chronic Obstructive Pulmonary Disease–Related Years of Life Lost as a Prognostic Signal
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853613
To the Editor Bhatt and colleagues have shown that chronic obstructive pulmonary disease (COPD) is associated with a shorter lifespan, even among people who never smoked. This is important for patients and clinicians. The next message is more subtle. The reported years of life lost should be read as a warning sign from baseline airflow obstruction, not as a direct measure of how many lost years COPD itself caused or how many years treatment can restore.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853613
To the Editor Bhatt and colleagues have shown that chronic obstructive pulmonary disease (COPD) is associated with a shorter lifespan, even among people who never smoked. This is important for patients and clinicians. The next message is more subtle. The reported years of life lost should be read as a warning sign from baseline airflow obstruction, not as a direct measure of how many lost years COPD itself caused or how many years treatment can restore.
Lasker Winners’ Work Leads to New Narcolepsy Treatment
https://jamanetwork.com/journals/jama/fullarticle/2854079
This Medical News article is an interview with Emmanuel Mignot, MD, PhD, and Masashi Yanagisawa, MD, PhD, winners of the 2026 Albert Lasker Basic Medical Research Award for their identification of the neuropeptide orexin and its role in narcolepsy.
https://jamanetwork.com/journals/jama/fullarticle/2854079
This Medical News article is an interview with Emmanuel Mignot, MD, PhD, and Masashi Yanagisawa, MD, PhD, winners of the 2026 Albert Lasker Basic Medical Research Award for their identification of the neuropeptide orexin and its role in narcolepsy.
The 2026 Albert Lasker Basic Medical Research Award
https://jamanetwork.com/journals/jama/fullarticle/2853866
In this Perspective, 2026 Albert Lasker Basic Medical Research Award winners Emmanuel Mignot, MD, PhD, and Masashi Yanagisawa, MD, PhD, discuss their identification of the brain peptide orexin and how it relates to sleep, specifically orexin deficiency and narcolepsy.
https://jamanetwork.com/journals/jama/fullarticle/2853866
In this Perspective, 2026 Albert Lasker Basic Medical Research Award winners Emmanuel Mignot, MD, PhD, and Masashi Yanagisawa, MD, PhD, discuss their identification of the brain peptide orexin and how it relates to sleep, specifically orexin deficiency and narcolepsy.
From Biological Insight to a New Class of Medicines for Hemophilia A
https://jamanetwork.com/journals/jama/fullarticle/2853865
In this Perspective, the 2026 Lasker-DeBakey Clinical Medical Research Award winners describe the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia, a life-threatening bleeding disorder caused by lack of factor VIII.
https://jamanetwork.com/journals/jama/fullarticle/2853865
In this Perspective, the 2026 Lasker-DeBakey Clinical Medical Research Award winners describe the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia, a life-threatening bleeding disorder caused by lack of factor VIII.
We Set Out to Break the Mold in Science Philanthropy—It’s Still Not Enough
https://jamanetwork.com/journals/jama/fullarticle/2853864
In this Perspective, 2026 Lasker-Bloomberg Public Service Award winner Michael J. Fox discusses his personal experience with and contribution to Parkinson disease research.
https://jamanetwork.com/journals/jama/fullarticle/2853864
In this Perspective, 2026 Lasker-Bloomberg Public Service Award winner Michael J. Fox discusses his personal experience with and contribution to Parkinson disease research.
Atrial Pseudomasses in Erdheim-Chester Disease
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853943
This case report discusses a diagnosis of Erdheim-Chester disease in a patient in their early 70s who presented with chest pain, dyspnea, weight loss, and atrial pseudomasses on echocardiography.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853943
This case report discusses a diagnosis of Erdheim-Chester disease in a patient in their early 70s who presented with chest pain, dyspnea, weight loss, and atrial pseudomasses on echocardiography.
Dynamic Mitral Obstruction by a Left-Sided Cardiac Sarcoma
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853942
This case report discusses mitral obstruction by a cardiac sarcoma in a woman aged 54 years who presented with progressive exertional dyspnea.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853942
This case report discusses mitral obstruction by a cardiac sarcoma in a woman aged 54 years who presented with progressive exertional dyspnea.
Sex-Specific Outcomes After Catheter Ablation for Atrial Fibrillation
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853941
This cross-sectional study uses pool data from 3 randomized clinical trials to examine sex-specific outcomes after catheter ablation for atrial fibrillation (AF) in patients with left ventricular systolic dysfunction.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853941
This cross-sectional study uses pool data from 3 randomized clinical trials to examine sex-specific outcomes after catheter ablation for atrial fibrillation (AF) in patients with left ventricular systolic dysfunction.
Arterial Inflammation and Checkpoint Inhibition
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853940
This cohort study examines the arterial and systemic inflammatory outcomes associated with immune checkpoint inhibitors and vascular endothelial growth factor inhibitors using positron emission tomography (PET).
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853940
This cohort study examines the arterial and systemic inflammatory outcomes associated with immune checkpoint inhibitors and vascular endothelial growth factor inhibitors using positron emission tomography (PET).
Cardiovascular Outcomes Trials in Clonal Hematopoiesis of Indeterminate Potential
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853939
This Special Communication describes the challenges of planning trials of clonal hematopoiesis of indeterminate potential (CHIP) and proposes a road map for advancing the evidence base for potential CHIP-targeted therapies.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853939
This Special Communication describes the challenges of planning trials of clonal hematopoiesis of indeterminate potential (CHIP) and proposes a road map for advancing the evidence base for potential CHIP-targeted therapies.
❤2
Incomplete Additional Contributions Section
https://jamanetwork.com/journals/jama/fullarticle/2854045
In the Original Investigation titled “Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial” published in the June 3, 2025, issue of JAMA, the Additional Contributions section was incomplete. That section should have included text acknowledging staff at the Massachusetts General Hospital Center for Addiction Medicine. This article has been corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2854045
In the Original Investigation titled “Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial” published in the June 3, 2025, issue of JAMA, the Additional Contributions section was incomplete. That section should have included text acknowledging staff at the Massachusetts General Hospital Center for Addiction Medicine. This article has been corrected online.
Rheumatoid Arthritis in Adults: A Review
https://jamanetwork.com/journals/jama/fullarticle/2853931
This Review discusses the pathogenesis, epidemiology, risk factors, clinical presentation, diagnosis, treatment, and prognosis of rheumatoid arthritis (RA).
https://jamanetwork.com/journals/jama/fullarticle/2853931
This Review discusses the pathogenesis, epidemiology, risk factors, clinical presentation, diagnosis, treatment, and prognosis of rheumatoid arthritis (RA).
Neuroprotective Therapy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/fullarticle/2854044
A remarkable era in acute ischemic stroke care is now coming to a close—the period of the “reperfusion revolution.” Over the past few decades, pharmacological and mechanical flow restoration therapies became steadily more effective. By restoring blood flow and terminating the ischemic period, reperfusion salvages those cerebral tissues not yet irreversibly injured. However, the reperfusion strategy in acute stroke care is now reaching its limits. Current endovascular thrombectomy approaches reopen over 85% of occluded arteries, leaving little scope for further advance. And successful reperfusion treatment alone clearly only partially solves the therapeutic challenge. Among patients with ischemic stroke due to large-vessel occlusion who receive endovascular thrombectomy, more than two-thirds nevertheless have a disabled final outcome. Restoring blood flow yields incomplete recoveries because some irreversible injury accrues before recanalization can be achieved and additional injury is generated by reperfusion itself. To fully eradicate stroke-related disability, complementary therapies are needed, including: bridging neuroprotection agents, which allow brain cells to tolerate ischemia until reperfusion is attained; reperfusion neuroprotection agents, which avert reperfusion injury; and neuroreparative agents, which promote postinjury reorganization of neurons and synapses.
https://jamanetwork.com/journals/jama/fullarticle/2854044
A remarkable era in acute ischemic stroke care is now coming to a close—the period of the “reperfusion revolution.” Over the past few decades, pharmacological and mechanical flow restoration therapies became steadily more effective. By restoring blood flow and terminating the ischemic period, reperfusion salvages those cerebral tissues not yet irreversibly injured. However, the reperfusion strategy in acute stroke care is now reaching its limits. Current endovascular thrombectomy approaches reopen over 85% of occluded arteries, leaving little scope for further advance. And successful reperfusion treatment alone clearly only partially solves the therapeutic challenge. Among patients with ischemic stroke due to large-vessel occlusion who receive endovascular thrombectomy, more than two-thirds nevertheless have a disabled final outcome. Restoring blood flow yields incomplete recoveries because some irreversible injury accrues before recanalization can be achieved and additional injury is generated by reperfusion itself. To fully eradicate stroke-related disability, complementary therapies are needed, including: bridging neuroprotection agents, which allow brain cells to tolerate ischemia until reperfusion is attained; reperfusion neuroprotection agents, which avert reperfusion injury; and neuroreparative agents, which promote postinjury reorganization of neurons and synapses.
Loberamisal for Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/fullarticle/2854043
This randomized clinical trial evaluates whether intravenous loberamisal improves functional outcomes and maintains an acceptable safety profile in patients with acute ischemic stroke treated within 48 hours of symptom onset.
https://jamanetwork.com/journals/jama/fullarticle/2854043
This randomized clinical trial evaluates whether intravenous loberamisal improves functional outcomes and maintains an acceptable safety profile in patients with acute ischemic stroke treated within 48 hours of symptom onset.
Patient Information: Psilocybin
https://jamanetwork.com/journals/jama/fullarticle/2854042
This JAMA Patient Page describes the psychedelic compound psilocybin, its medical and recreational use, and its potential side effects.
https://jamanetwork.com/journals/jama/fullarticle/2854042
This JAMA Patient Page describes the psychedelic compound psilocybin, its medical and recreational use, and its potential side effects.
Loberamisal for Acute Ischemic Stroke Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2854041
This trial evaluated whether intravenous loberamisal improves functional outcomes and is safe in adults with acute ischemic stroke treated within 48 hours of symptom onset.
https://jamanetwork.com/journals/jama/fullarticle/2854041
This trial evaluated whether intravenous loberamisal improves functional outcomes and is safe in adults with acute ischemic stroke treated within 48 hours of symptom onset.
Medicine’s Role in Mental Health Promotion
https://jamanetwork.com/journals/jama/fullarticle/2853937
Dana L. Farnsworth, M.D., Cambridge, Mass.
https://jamanetwork.com/journals/jama/fullarticle/2853937
Dana L. Farnsworth, M.D., Cambridge, Mass.
Psilocybin
https://jamanetwork.com/journals/jama/fullarticle/2853938
This JAMA Insights discusses the medical use of psilocybin, particularly for depression treatment, including emerging potential indications, safety, and future use.
https://jamanetwork.com/journals/jama/fullarticle/2853938
This JAMA Insights discusses the medical use of psilocybin, particularly for depression treatment, including emerging potential indications, safety, and future use.
❤1🔥1
Audio Highlights September 11, 2026
https://jamanetwork.com/journals/jama/fullarticle/2854237
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2854237
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.